



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Art Unit: 1653

CAVANAK ET AL.

Examiner: J. Russel

Application No.: 10/790,543

Dated: July 8, 2005

Filed: MARCH 1, 2004

For: NOVEL CYCLOSPORIN GALENIC FORMS

MAILSTOP RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

This paper is part of a submission under 37 C.F.R. §1.114. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 04-1121.

In accordance with 37 C.F.R. §1.56, Applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO 1449.

The listed references are of record in grandparent Application No. 09/931,680, now U.S. Patent 6,468,968, and copies are available therein. Applicants are enclosing a copy of U.S. Patent 6,468,968 and are willing to send copies of any of all of the remaining references at the Examiner's request.

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to the: U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 on July 8, 2005.

Dated: July 8, 2005

  
\_\_\_\_\_  
Margaret Leone

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO-1449 forms.

Respectfully submitted,




Ann R. Pokalsky  
Reg. No. 34,697  
Attorney for Applicants

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7859

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket No. 100-6403R/C4N1C4AD1D1C1 (167-43)  
 Application No.: 10/790,543  
 Applicant: Cavanak et al.  
 Filing Date: March 1, 2004  
 Sheet 1 of 3

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA	3,288,824	11/29/66	Mahler et al.	760	410.6	
AB	4,108,985	8/22/78	Ruegger et al.	424	177	
AC	4,210,581	7/1/80	Ruegger et al.	260	112.5	
AD	4,220,641	9/2/80	Traber et al.	424	177	
AE	4,388,307	6/14/83	Cavanak	424	177	
AF	4,719,239	1/12/88	Muller et al	514	785	2/22/85
AG	5,338,761	8/16/94	Nakajima et al.	514	772	
AH	5,639,724	6/17/97	Cavanak	514	11	
AI	5,652,212	7/29/97	Cavanak et al.	514	11	
AJ	5,759,997	6/2/98	Cavanak	514	11	
AK	4,390,548	6/1/83	Yamato et al.	424	321	
AL	5,977,066	11/2/99	Cavanak	514	11	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
AM	0,170,623	2/5/86	EPO			<input type="checkbox"/> <input type="checkbox"/>
AN	2,098,865	12/1/82	Great Britain			<input type="checkbox"/> <input type="checkbox"/>
AO	2,120,935	12/14/83	Great Britain			<input type="checkbox"/> <input type="checkbox"/>
AP	2,211,848	7/12/89	Great Britain			<input type="checkbox"/> <input type="checkbox"/>
AQ	2461/78-6	6/14/83	Swiss			<input type="checkbox"/> <input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Cavanak et al., Prog. Allergy, Vol. 38, pp.65-72 j(1986)
AS	Eckert et al., Chemical Abstracts, 89: 117875t (6/8/78)
AT	Chemical Abstracts, 89: 117874s (6/8/78)

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket No.: 100-6403R/C4N1C4AD1D1C1 (167-43)  
Application No.: 10/790,543  
Applicant: Cavanak et al.  
Filing Date: March 1, 2004  
Sheet 2 of 3

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

A A	Takada et al., Int. J. of Pharmaceuticals Vol. 44; 107-116 (1988)
A B	Chemical Abstracts, 95: 225610K (1981)
A C	Simpson et al., Chemical Abstracts 94: 327C (1981)
A D	Takada et al., J. Pharmacobio-Dyn. Vol. 11: 80-87 (1988)
A E	Reymond et al., Pharmaceutical Research, vol. 5, No. 10, pp. 673-676 (1988)
A F	Reymond, University of Basel (1986) Dissertation: In vitro In Vivo Model for the Absorption of Cyclosporin A.
A G	Cavanak, Chemical Abstracts, 92: 64765k (1980)
A H	Derwent Abstracts, 84-069426/12 (2/19/84). (Abstract of JA 61/280,435, Published December 11, 1986)
A I	Miglyol-Neutral Oil, Dynamit Nobel Chemicals (1975)
A J	
A K	
A L	
A M	
A N	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket No.: 100-6403R/C4N1C4AD1D1C1 (167-40)  
Application No.: 10/790,543  
Applicant: Cananak et al.  
Filing Date: March 1, 2004  
Sheet 3 of 3

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,996,193	2/26/91	Hewitt et al.	514	11	
	AB	4,990,337	2/5/91	Kurihara et al.	424	427	
	AC	4,073,920	2/14/78	Dowrick	514	193	
	AD	5,342,625	8/30/94	Hauer et al.	424	455	
	AE	6,306,825	10/23/01	Cavanak	514	11	
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM	641356	2/29/84	Swiss			<input type="checkbox"/>	<input type="checkbox"/>
	AN	8634/78-8	6/14/83	Swiss			<input type="checkbox"/>	<input type="checkbox"/>
	AO	895,724	7/28/83	Belgium			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	
AS	
AT	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.